Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in recurrent ovarian cancer
2010-023035-42Phase 3Active
- Sponsor
- Unicancer
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in epithelial ovarian cancer (EOC) (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival. Started Dec 2010; status: active.
02
Drugs
cisplatin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2010-023035-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023035-42.